Please sign in to follow a disease.
Serous adenocarcinoma
MONDO:0005278An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present. Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.
Also known as: serous adenocarcinoma, serous carcinoma, serous cystadenocarcinoma, serous cystadenocarcinoma, NOS (morphologic abnormality)
2977 clinical trials for this condition and its sub-types, 6 tagged with Serous adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Serous adenocarcinoma
-
Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types
3 sub-types
-
Fallopian tube serous adenocarcinoma 71 trials
-
Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types
1 sub-type
- Primary peritoneal serous adenocarcinoma 36 trials · 38 incl. sub-types Sub-types →
-
Endometrial serous adenocarcinoma 36 trials
-
Serous cystadenocarcinoma 1 trial · 5 incl. sub-types
3 sub-types
- Ovarian serous cystadenocarcinoma 4 trials
- Pancreatic serous cystadenocarcinoma 0 trials
- Papillary serous cystadenocarcinoma 0 trials
-
Cervical serous adenocarcinoma 0 trials
1 sub-type
-
New hope for tough ovarian cancer: phase 3 trial of Mo-Rez drug launches
Disease control Recruiting nowThis study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New vaccine aims to outsmart ovarian cancer recurrence
Disease control Recruiting nowThis phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC